Predicted protein targets (top 8)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PDE5A | O76074 | 6/20 | 0.63 |
| ▸ | AURKA | O14965 | 6/20 | 0.48 |
| ▸ | HPSE | Q9Y251 | 1/20 | 0.47 |
| ▸ | METAP1 | P53582 | 2/20 | 0.47 |
| ▸ | WNT1 | P04628 | 2/20 | 0.46 |
| ▸ | METAP2 | P50579 | 1/20 | 0.46 |
| ▸ | PDE2A | O00408 | 1/20 | 0.45 |
| ▸ | GUSB | P08236 | 1/20 | 0.45 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL14090248 | 0.91 | PDE5A (0.68) | PDE5AAURKAHPSEMETAP1METAP2 | |
| SCHEMBL14090254 | 0.88 | WNT1 (0.61) | PDE5AAURKAHPSEMETAP1WNT1 | |
| SCHEMBL14090208 | 0.85 | AURKA (0.69) | PDE5AAURKAPDE2A | |
| SCHEMBL14090269 | 0.85 | PDE5A (0.57) | PDE5AAURKAHPSEMETAP1METAP2 | |
| SCHEMBL14090380 | 0.85 | PDE5A (0.67) | PDE5AAURKAHPSEMETAP1METAP2 | |
| SCHEMBL14090223 | 0.84 | PDE5A (0.59) | PDE5AAURKAHPSEMETAP1WNT1 | |
| SCHEMBL14090240 | 0.82 | PDE5A (0.64) | PDE5AAURKAHPSEMETAP1METAP2 | |
| SCHEMBL14090228 | 0.82 | PDE5A (0.60) | PDE5AAURKAPDE2A | |
| SCHEMBL11155883 | 0.79 | AURKA (0.67) | PDE5AAURKAHPSEMETAP1METAP2 | |
| SCHEMBL7430084 | 0.78 | PDE5A (1.00) | PDE5AAURKAMETAP1METAP2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8629147-B2 | Heterocyclic compounds useful in the treatment of neoplastic diseases, inflammatory disorders and immunomodulatory disorders | CHEMBRIDGE CORPORATION (US) | 2014-01-14 | — | — | US | disclosed |
| US-8629147-B2 | Heterocyclic compounds useful in the treatment of neoplastic diseases, inflammatory disorders and immunomodulatory disorders | CHEMBRIDGE CORPORATION (US) | 2014-01-14 | — | — | US | disclosed |
| US-20080207635-A1 | Heterocyclic compounds useful in the treatment of neoplastic diseases, inflammatory disorders and immunomodulatory disorders | CHEMBRIDGE CORPORATION | 2008-08-28 | — | — | US | disclosed |
| US-20080207635-A1 | Heterocyclic compounds useful in the treatment of neoplastic diseases, inflammatory disorders and immunomodulatory disorders | CHEMBRIDGE CORPORATION | 2008-08-28 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20080207635-A1 | Heterocyclic compounds useful in the treatment of neoplastic diseases, inflammatory disorders and immunomodulatory disorders | LCK, MALT1, MYD88 | PDE5A 2213/4885AURKA 780/4885HPSE 1373/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.